2-Chloro-6-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol → HCID 66715518, compound
Reaction equation
Br[C:2]1[CH:3]=[C:4]2[C:9](=[CH:10][CH:11]=1)[N:8]=[CH:7][C:6]([C:12]([CH:14]1[CH2:16][CH2:15]1)=[O:13])=[C:5]2[NH:17][C:18]1[CH:19]=[N:20][C:21]([N:24]2[CH2:29][CH2:28][CH2:27][CH:26]([NH:30]C(=O)OC(C)(C)C)[CH2:25]2)=[N:22][CH:23]=1.[Cl:38][C:39]1[CH:44]=[C:43](B2OC(C)(C)C(C)(C)O2)[CH:42]=[C:41]([F:54])[C:40]=1[OH:55]>>[NH2:30][CH:26]1[CH2:27][CH2:28][CH2:29][N:24]([C:21]2[N:20]=[CH:19][C:18]([NH:17][C:5]3[C:4]4[C:9](=[CH:10][CH:11]=[C:2]([C:43]5[CH:42]=[C:41]([F:54])[C:40]([OH:55])=[C:39]([Cl:38])[CH:44]=5)[CH:3]=4)[N:8]=[CH:7][C:6]=3[C:12]([CH:14]3[CH2:16][CH2:15]3)=[O:13])=[CH:23][N:22]=2)[CH2:25]1Participants
Procedure
Following general procedure D, tert-butyl 1-(5-(6-bromo-3-(cyclopropanecarbonyl)quinolin-4-ylamino)pyrimidin-2-yl)piperidin-3-ylcarbamate (150 mg, 0.26 mmol) was reacted with 2-chloro-6-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (106 mg, 0.39 mmol) to obtain the protected intermediate which was subjected to general procedure A-2 to afford the desired product (28 mg, 23% over 2 steps) as a yellow solid. NMR (500 MHz, MeOD+TFA-d) δ 9.34 (br s, 1H), 8.45 (s, 2H), 8.25 (dd, J=8.8, 1.9 Hz, 1H), 8.21 (br s, 1H), 8.04 (d, J=8.8 Hz, 1H), 7.25 (br s, 1H), 4.81-4.74 (m, 1H), 4.47 (d, J=12.8 Hz, 1H), 3.48-3.31 (m, 3H), 2.80 (br s, 1H), 2.24-2.16 (m, 1H), 1.97-1.87 (m, 1H), 1.81-1.62 (m, 2H), 1.21-1.16 (m, J=7.3 Hz, 4H); ESI MS m/z 533 [C28H26ClFN6O2+H]+; HPLC>99.0% (AUC), tR=10.89 min.
Workup
- customto obtain the protected intermediate which
Sources & evidence
- ORD record
- ord-6b870c7ead5b425291d89cc536358f22
- Source dataset
- uspto-grants-2015_09
- Patent number
- US09120749B2
Reaction notes
Loading…